Authors response to “Letter to the Editor”: “Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types” by David R Gandara, Ryon P Graf

Get full text

Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications by David P Carbone, Igor Puzanov, Ronan J Kelly, Yuval Shaked, Michal Harel, Coren Lahav, Eyal Jacob, Nili Dahan, David R Gandara, Yehonatan Elon, Adam P Dicker, Raya Leibowitz

Get full text

International society of liquid biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors by Nicola Fusco, Konstantinos Venetis, Francesco Pepe, Omshree Shetty, Silvia Calabuig Farinas, Simon Heeke, Julia V. Burnier, Simon J. Patton, Ellen Heitzer, Giovanni Nigita, Paul Hofman, Maria Jose Serrano, Massimo Cristofanilli, Eloisa Jantus-Lewintre, David R. Gandara, Christian Rolfo, Umberto Malapelle

Get full text

A Phase 1/1B Trial of Pembrolizumab and Trametinib in Advanced NSCLC Enriched for KRAS Mutations by Jonathan W. Riess, MD, MS, Matthew S. Lara, BS, Guillaume Luxardi, PhD, Miguel Lopez de Rodas, MD, Michiko Shimoda, PhD, Karen Kelly, MD, Primo N. Lara, MD, Laurel Beckett, PhD, Arta Monjazeb, MD, PhD, Kurt A. Schalper, MD, PhD, Emanual Maverakis, MD, David R. Gandara, MD

Get full text

Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types by Vivek Subbiah, Samuel J Klempner, Neeraj Agarwal, David P Carbone, Amit Mahipal, Shilpa Gupta, David Fabrizio, Jeffrey S Ross, Gerald Li, David R Gandara, Miles C Andrews, Jonathan W Riess, Ramez N Eskander, Ryon P Graf, Geoffrey R Oxnard, Sarah Sammons, Jeremy Snider, Lilia Bouzit, Cheryl Cho-Phan, Megan Price, Julia C F Quintanilha, Richard Sheng Poe Huang

Get full text